A synthetic heart valve is made from a valve graft of synthetic material and more particularly expanded polytetrafluoroethylene (ePTFE). The valve graft has an upper portion defined by a first thickness and a lower portion defined by a second thickness which is greater than the first thickness. The valve graft is formed into a cylindrical sleeve having a diameter and a folded region. A flexible stent overlays the cylindrical sleeve, wherein a series of leaflets are formed in the lower portion of the sleeve, the leaflets defining a semicircular perimeter. The leaflets are sutured to the cylindrical sleeve and the cylindrical sleeve is sutured to the flexible stent, the stent having a plurality of bent cylindrical wire segments that are welded together and in which the sleeve is sutured to the wire, including the welded areas of the stent. The formed valve can be implanted using a balloon catheter.

A synthetic heart valve is made from a valve graft of synthetic material and more particularly expanded polytetrafluoroethylene (ePTFE). The valve graft has an upper portion defined by a first thickness and a lower portion defined by a second thickness which is greater than the first thickness. The valve graft is formed into a cylindrical sleeve having a diameter and a folded region. A flexible stent overlays the cylindrical sleeve, wherein a series of leaflets are formed in the lower portion of the sleeve, the leaflets defining a semicircular perimeter. The leaflets are sutured to the cylindrical sleeve and the cylindrical sleeve is sutured to the flexible stent, the stent having a plurality of bent cylindrical wire segments that are welded together and in which the sleeve is sutured to the wire, including the welded areas of the stent. The formed valve can be implanted using a balloon catheter.

A suture to be used in producing a medical instrument provided with a sutured site such as a stent graft, an artificial blood vessel or an artificial heart valve, has two components, i.e., a high melting-point component and a low-melting point component, the difference between the melting points of components being 30° C. or more and the low-melting point component is exposed on the suture surface entirely along the length direction. When a medical material formed of a fabric or a film is sutured or knotted with the suture and then the suture site is heated at such a temperature not allowing the high-melting point component but the low-melting point component alone to melt, the sutured site is fused and fixed. Thus, a knot or a seam, which sustains the fiber shape and strength and never becomes loose, can be formed.

A suture to be used in producing a medical instrument provided with a sutured site such as a stent graft, an artificial blood vessel or an artificial heart valve, has two components, i.e., a high melting-point component and a low-melting point component, the difference between the melting points of components being 30° C. or more and the low-melting point component is exposed on the suture surface entirely along the length direction. When a medical material formed of a fabric or a film is sutured or knotted with the suture and then the suture site is heated at such a temperature not allowing the high-melting point component but the low-melting point component alone to melt, the sutured site is fused and fixed. Thus, a knot or a seam, which sustains the fiber shape and strength and never becomes loose, can be formed.

The present invention provides peptidic TGF-β antagonists capable of inhibiting TGF-β signaling and disrupting the biochemical events that promote fibrosis and the epithelial-mesenchymal transition. The peptidic TGF-β antagonist may contain from 11 to 28 amino acid residues (for instance, may consist of from 12 to 16 amino acid residues) and may have the following structure (II):
NH.sub.2′ETWIWLDTNMG-Xaa.sub.1-Y′COOH  (II)
wherein Xaa.sub.1 is any amino acid and Y is a peptide having from 0 to 9 amino acids. The peptidic TGF-β antagonists can advantageously be used for the prevention, treatment, and/or alleviation of the symptoms of a condition associated with an increase in TGF-β activity, including fibrosis (such as fibrosis of the skin, liver, lungs, and heart, among others) and cancer (including various carcinomas, such as squamous cell carcinoma, sarcomas, and metastatic cancers).

Compositions, methods, devices, and systems are provided comprising a polymer having one or more sensors.

Compositions, methods, devices, and systems are provided comprising a polymer having one or more sensors.

A disposable coating applicator container for applying a coating of a therapeutic agent upon an object to be coated. The disposable coating applicator container includes a sealable container, the sealable container having a container bottom, the container bottom having upwardly extending walls, each upwardly extending wall terminating in an upper edge, and a closure for sealing a device compartment formed in part by the upwardly extending walls, the closure adjacent to the upper edges of the upwardly extending walls; and a therapeutic agent positioned in fluid communication with the device compartment, wherein the disposable coating applicator container comprises a flexible material and is in the form of a bag-like structure.

A staple cartridge comprising a cartridge deck, a longitudinal slot defined within the staple cartridge, staple cavities defined in the deck, and a tissue thickness compensator is disclosed. The tissue thickness compensator comprises lumens. Each of the lumens comprise a cross-section and are formed by a tubular element. The lumens are laterally-oriented and spaced on the cartridge deck along the longitudinal axis of the staple cartridge. Each lumen extends across the width of the staple cartridge such that each lumen overlaps a plurality of the staple cavities and the longitudinal slot. The lumens are configured to collapse when pressure is applied to the lumens during a firing motion.

Novel, lubricious coatings for medical devices are disclosed. The coatings provide improved lubricity and durability and are readily applied in coating processes a low temperatures that do not deform the device. The present invention is also directed to a novel platinum catalyst for use in such coatings. The catalyst provides for rapid curing, while inhibiting cross-linking at ambient temperatures, thereby improving the production pot life of the coatings.